In December, OHE announced that Professor Mike Drummond , Professor Bengt Jonnson, and Louise Timlin were stepping down from the OHE Board of Trustees.

OHE is pleased to welcome Patrick Holmes to the Board of Trustees effective 31 January 2022. OHE’s Chief Executive, Professor Graham Cookson says, “We’re delighted to welcome Patrick Holmes to the Board. He is a well-renowned expert on developing global policy initiatives to drive affordable patient access to innovative medicines which is core to OHE’s mission.”

Patrick Holmes is an industry veteran with over 30 years of experience in the pharmaceutical industry in a broad range of roles, most notably in the global policy arena.  Patrick is the Science and Innovation Policy Lead at Pfizer based in New York and heads a team responsible for developing global health policy initiatives and evidence across a series of policy issues supporting Pfizer’s R&D-driven organization, including driving affordable patient access to medicines, while allowing the company to continue to develop and deliver innovative treatments. Issue areas include market-based R&D incentives, value and innovation frameworks and sustainable patient-centric health systems. All areas of significant interest to OHE’s researchers.

As more than 80% of OHE’s consultancy work is international, Patrick will bring invaluable oversight and counsel to OHE’s executive team. He has significant experience of working on topics such as AMR that OHE is well-known for, and with international and multilateral organisations such as Business @ OECD Health Committee, the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) Value and Access and Pandemic Preparedness Working Groups, Innovation and Value Initiative (IVI) Scientific Advisory Panel and the European Federation of Pharmaceutical Industries and Associations (EFPIA) Healthcare Systems Working Group. Further, as OHE continues to develop a portfolio of research and consulting in the US policy arena Patrick’s experience with the US health system will be invaluable.

Patrick brings a range of experiences to his current role having worked across multiple areas of the biopharmaceutical business during his 30-year career at Pfizer. Patrick joined Pfizer as a marketing associate in 1990 and held multiple positions of increasing responsibility in both US and global marketing spanning a range of therapeutic areas including hypertension, lipid lowering, arrhythmia, diabetes, erectile dysfunction, and allergies. Patrick then switched to a strategic planning role where he was responsible for evaluating new product opportunities and providing strategic input on behalf of the US commercial organization. He then led the Portfolio and Decision Analysis group, supporting strategic decisions and investment tradeoffs across Pfizer’s development portfolio. His last assignment prior to joining the policy team was Vice President, Strategy and Portfolio Support, providing comprehensive insights and identifying key emerging trends for Pfizer leaders.

Patrick has a BA in biology from Middlebury College and an MS in management from the Massachusetts Institute of Technology Sloan School of Management. He joins the Board in a personal capacity.